The global market for Drugs for Herpes Labialis (Oral Herpes) was estimated to be worth US$ 2458 million in 2023 and is forecast to a readjusted size of US$ 3449.3 million by 2030 with a CAGR of 4.9% during the forecast period 2024-2030

Drugs for Herpes Labialis (Oral Herpes) - Market

Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2–3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.

Global Drugs for Herpes Labialis (Oral Herpes) key players include GSK, Novartis, Teva, Mylan, Cadila, etc. Global top five manufacturers hold a share about 55%. North America is the largest market, with a share about 35%, followed by Europe, with a share about 30 percent. In terms of product, Rx Drugs is the largest segment, with a share about 90%. And in terms of application, the largest application is Oral, followed by External Use, and Injection, etc.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Drugs for Herpes Labialis (Oral Herpes), focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Drugs for Herpes Labialis (Oral Herpes) by region & country, by Type, and by Application.

The Drugs for Herpes Labialis (Oral Herpes) market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Herpes Labialis (Oral Herpes).

Market Segmentation

Scope of Drugs for Herpes Labialis (Oral Herpes) - Market Report

Report Metric	Details
Report Name	Drugs for Herpes Labialis (Oral Herpes) - Market
Forecasted market size in 2030	US$ 3449.3 million
CAGR	4.9%
Forecasted years	2024 - 2030
Segment by Type:	Aciclovir Valacyclovir Famciclovir Docosanol Other
Segment by Application	External Use Oral Injection
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	GSK, Novartis, Teva, Mylan, Cadila, Apotex, Daewoong Pharmaceutical, Livzon, Luoxin, Med shine, Bayer (Campho Phenique), Blistex, Kelun, Hikma, Haiwang, Carmex, Cipher
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Drugs for Herpes Labialis (Oral Herpes) manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Drugs for Herpes Labialis (Oral Herpes) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Drugs for Herpes Labialis (Oral Herpes) in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Drugs for Herpes Labialis (Oral Herpes) - Market size in 2030?

Ans: The Drugs for Herpes Labialis (Oral Herpes) - Market size in 2030 will be US$ 3449.3 million.

What is the market share of major companies in Drugs for Herpes Labialis (Oral Herpes) - Market?

Ans: Global top five manufacturers hold a share about 55%.

Who are the main players in the Drugs for Herpes Labialis (Oral Herpes) - Market report?

Ans: The main players in the Drugs for Herpes Labialis (Oral Herpes) - Market are GSK, Novartis, Teva, Mylan, Cadila, Apotex, Daewoong Pharmaceutical, Livzon, Luoxin, Med shine, Bayer (Campho Phenique), Blistex, Kelun, Hikma, Haiwang, Carmex, Cipher

What are the Application segmentation covered in the Drugs for Herpes Labialis (Oral Herpes) - Market report?

Ans: The Applications covered in the Drugs for Herpes Labialis (Oral Herpes) - Market report are External Use, Oral, Injection

What are the Type segmentation covered in the Drugs for Herpes Labialis (Oral Herpes) - Market report?

Ans: The Types covered in the Drugs for Herpes Labialis (Oral Herpes) - Market report are Aciclovir, Valacyclovir, Famciclovir, Docosanol, Other

1 Market Overview

1.1 Drugs for Herpes Labialis (Oral Herpes) Product Introduction

1.2 Global Drugs for Herpes Labialis (Oral Herpes) Market Size Forecast

1.3 Drugs for Herpes Labialis (Oral Herpes) Market Trends & Drivers

1.3.1 Drugs for Herpes Labialis (Oral Herpes) Industry Trends

1.3.2 Drugs for Herpes Labialis (Oral Herpes) Market Drivers & Opportunity

1.3.3 Drugs for Herpes Labialis (Oral Herpes) Market Challenges

1.3.4 Drugs for Herpes Labialis (Oral Herpes) Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Drugs for Herpes Labialis (Oral Herpes) Players Revenue Ranking (2023)

2.2 Global Drugs for Herpes Labialis (Oral Herpes) Revenue by Company (2019-2024)

2.3 Key Companies Drugs for Herpes Labialis (Oral Herpes) Manufacturing Base Distribution and Headquarters

2.4 Key Companies Drugs for Herpes Labialis (Oral Herpes) Product Offered

2.5 Key Companies Time to Begin Mass Production of Drugs for Herpes Labialis (Oral Herpes)

2.6 Drugs for Herpes Labialis (Oral Herpes) Market Competitive Analysis

2.6.1 Drugs for Herpes Labialis (Oral Herpes) Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Drugs for Herpes Labialis (Oral Herpes) Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Herpes Labialis (Oral Herpes) as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Aciclovir

3.1.2 Valacyclovir

3.1.3 Famciclovir

3.1.4 Docosanol

3.1.5 Other

3.2 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Type

3.2.1 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value, by Type (2019-2030)

3.2.3 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 External Use

4.1.2 Oral

4.1.3 Injection

4.2 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Application

4.2.1 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value, by Application (2019-2030)

4.2.3 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Region

5.1.1 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Region (2019-2024)

5.1.3 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Region (2025-2030)

5.1.4 Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Drugs for Herpes Labialis (Oral Herpes) Sales Value, 2019-2030

5.2.2 North America Drugs for Herpes Labialis (Oral Herpes) Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Drugs for Herpes Labialis (Oral Herpes) Sales Value, 2019-2030

5.3.2 Europe Drugs for Herpes Labialis (Oral Herpes) Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Drugs for Herpes Labialis (Oral Herpes) Sales Value, 2019-2030

5.4.2 Asia Pacific Drugs for Herpes Labialis (Oral Herpes) Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Drugs for Herpes Labialis (Oral Herpes) Sales Value, 2019-2030

5.5.2 South America Drugs for Herpes Labialis (Oral Herpes) Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Sales Value, 2019-2030

5.6.2 Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Drugs for Herpes Labialis (Oral Herpes) Sales Value

6.3 United States

6.3.1 United States Drugs for Herpes Labialis (Oral Herpes) Sales Value, 2019-2030

6.3.2 United States Drugs for Herpes Labialis (Oral Herpes) Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Drugs for Herpes Labialis (Oral Herpes) Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Drugs for Herpes Labialis (Oral Herpes) Sales Value, 2019-2030

6.4.2 Europe Drugs for Herpes Labialis (Oral Herpes) Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Drugs for Herpes Labialis (Oral Herpes) Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Drugs for Herpes Labialis (Oral Herpes) Sales Value, 2019-2030

6.5.2 China Drugs for Herpes Labialis (Oral Herpes) Sales Value by Type (%), 2023 VS 2030

6.5.3 China Drugs for Herpes Labialis (Oral Herpes) Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Drugs for Herpes Labialis (Oral Herpes) Sales Value, 2019-2030

6.6.2 Japan Drugs for Herpes Labialis (Oral Herpes) Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Drugs for Herpes Labialis (Oral Herpes) Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Drugs for Herpes Labialis (Oral Herpes) Sales Value, 2019-2030

6.7.2 South Korea Drugs for Herpes Labialis (Oral Herpes) Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Drugs for Herpes Labialis (Oral Herpes) Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Drugs for Herpes Labialis (Oral Herpes) Sales Value, 2019-2030

6.8.2 Southeast Asia Drugs for Herpes Labialis (Oral Herpes) Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Drugs for Herpes Labialis (Oral Herpes) Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Drugs for Herpes Labialis (Oral Herpes) Sales Value, 2019-2030

6.9.2 India Drugs for Herpes Labialis (Oral Herpes) Sales Value by Type (%), 2023 VS 2030

6.9.3 India Drugs for Herpes Labialis (Oral Herpes) Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 GSK

7.1.1 GSK Profile

7.1.2 GSK Main Business

7.1.3 GSK Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

7.1.4 GSK Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2019-2024)

7.1.5 GSK Recent Developments

7.2 Novartis

7.2.1 Novartis Profile

7.2.2 Novartis Main Business

7.2.3 Novartis Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

7.2.4 Novartis Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2019-2024)

7.2.5 Novartis Recent Developments

7.3 Teva

7.3.1 Teva Profile

7.3.2 Teva Main Business

7.3.3 Teva Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

7.3.4 Teva Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2019-2024)

7.3.5 Mylan Recent Developments

7.4 Mylan

7.4.1 Mylan Profile

7.4.2 Mylan Main Business

7.4.3 Mylan Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

7.4.4 Mylan Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2019-2024)

7.4.5 Mylan Recent Developments

7.5 Cadila

7.5.1 Cadila Profile

7.5.2 Cadila Main Business

7.5.3 Cadila Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

7.5.4 Cadila Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2019-2024)

7.5.5 Cadila Recent Developments

7.6 Apotex

7.6.1 Apotex Profile

7.6.2 Apotex Main Business

7.6.3 Apotex Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

7.6.4 Apotex Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2019-2024)

7.6.5 Apotex Recent Developments

7.7 Daewoong Pharmaceutical

7.7.1 Daewoong Pharmaceutical Profile

7.7.2 Daewoong Pharmaceutical Main Business

7.7.3 Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

7.7.4 Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2019-2024)

7.7.5 Daewoong Pharmaceutical Recent Developments

7.8 Livzon

7.8.1 Livzon Profile

7.8.2 Livzon Main Business

7.8.3 Livzon Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

7.8.4 Livzon Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2019-2024)

7.8.5 Livzon Recent Developments

7.9 Luoxin

7.9.1 Luoxin Profile

7.9.2 Luoxin Main Business

7.9.3 Luoxin Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

7.9.4 Luoxin Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2019-2024)

7.9.5 Luoxin Recent Developments

7.10 Med shine

7.10.1 Med shine Profile

7.10.2 Med shine Main Business

7.10.3 Med shine Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

7.10.4 Med shine Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2019-2024)

7.10.5 Med shine Recent Developments

7.11 Bayer (Campho Phenique)

7.11.1 Bayer (Campho Phenique) Profile

7.11.2 Bayer (Campho Phenique) Main Business

7.11.3 Bayer (Campho Phenique) Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

7.11.4 Bayer (Campho Phenique) Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2019-2024)

7.11.5 Bayer (Campho Phenique) Recent Developments

7.12 Blistex

7.12.1 Blistex Profile

7.12.2 Blistex Main Business

7.12.3 Blistex Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

7.12.4 Blistex Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2019-2024)

7.12.5 Blistex Recent Developments

7.13 Kelun

7.13.1 Kelun Profile

7.13.2 Kelun Main Business

7.13.3 Kelun Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

7.13.4 Kelun Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2019-2024)

7.13.5 Kelun Recent Developments

7.14 Hikma

7.14.1 Hikma Profile

7.14.2 Hikma Main Business

7.14.3 Hikma Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

7.14.4 Hikma Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2019-2024)

7.14.5 Hikma Recent Developments

7.15 Haiwang

7.15.1 Haiwang Profile

7.15.2 Haiwang Main Business

7.15.3 Haiwang Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

7.15.4 Haiwang Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2019-2024)

7.15.5 Haiwang Recent Developments

7.16 Carmex

7.16.1 Carmex Profile

7.16.2 Carmex Main Business

7.16.3 Carmex Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

7.16.4 Carmex Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2019-2024)

7.16.5 Carmex Recent Developments

7.17 Cipher

7.17.1 Cipher Profile

7.17.2 Cipher Main Business

7.17.3 Cipher Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

7.17.4 Cipher Drugs for Herpes Labialis (Oral Herpes) Revenue (US$ Million) & (2019-2024)

7.17.5 Cipher Recent Developments

8 Industry Chain Analysis

8.1 Drugs for Herpes Labialis (Oral Herpes) Industrial Chain

8.2 Drugs for Herpes Labialis (Oral Herpes) Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Drugs for Herpes Labialis (Oral Herpes) Sales Model

8.5.2 Sales Channel

8.5.3 Drugs for Herpes Labialis (Oral Herpes) Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Daewoong Pharmaceutical

LIVZON

Luoxin

Med shine

Bayer (Campho Phenique)

List of Tables

Table 1. Drugs for Herpes Labialis (Oral Herpes) Market Trends

Table 2. Drugs for Herpes Labialis (Oral Herpes) Market Drivers & Opportunity

Table 3. Drugs for Herpes Labialis (Oral Herpes) Market Challenges

Table 4. Drugs for Herpes Labialis (Oral Herpes) Market Restraints

Table 5. Global Drugs for Herpes Labialis (Oral Herpes) Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Drugs for Herpes Labialis (Oral Herpes) Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Drugs for Herpes Labialis (Oral Herpes) Product Type

Table 9. Key Companies Time to Begin Mass Production of Drugs for Herpes Labialis (Oral Herpes)

Table 10. Global Drugs for Herpes Labialis (Oral Herpes) Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Herpes Labialis (Oral Herpes) as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Drugs for Herpes Labialis (Oral Herpes) Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Drugs for Herpes Labialis (Oral Herpes) Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Drugs for Herpes Labialis (Oral Herpes) Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Drugs for Herpes Labialis (Oral Herpes) Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Region (2019-2024) & (%)

Table 27. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Drugs for Herpes Labialis (Oral Herpes) Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Drugs for Herpes Labialis (Oral Herpes) Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Drugs for Herpes Labialis (Oral Herpes) Sales Value, (2025-2030) & (US$ Million)

Table 31. GSK Basic Information List

Table 32. GSK Description and Business Overview

Table 33. GSK Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

Table 34. Revenue (US$ Million) in Drugs for Herpes Labialis (Oral Herpes) Business of GSK (2019-2024)

Table 35. GSK Recent Developments

Table 36. Novartis Basic Information List

Table 37. Novartis Description and Business Overview

Table 38. Novartis Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

Table 39. Revenue (US$ Million) in Drugs for Herpes Labialis (Oral Herpes) Business of Novartis (2019-2024)

Table 40. Novartis Recent Developments

Table 41. Teva Basic Information List

Table 42. Teva Description and Business Overview

Table 43. Teva Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

Table 44. Revenue (US$ Million) in Drugs for Herpes Labialis (Oral Herpes) Business of Teva (2019-2024)

Table 45. Teva Recent Developments

Table 46. Mylan Basic Information List

Table 47. Mylan Description and Business Overview

Table 48. Mylan Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

Table 49. Revenue (US$ Million) in Drugs for Herpes Labialis (Oral Herpes) Business of Mylan (2019-2024)

Table 50. Mylan Recent Developments

Table 51. Cadila Basic Information List

Table 52. Cadila Description and Business Overview

Table 53. Cadila Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

Table 54. Revenue (US$ Million) in Drugs for Herpes Labialis (Oral Herpes) Business of Cadila (2019-2024)

Table 55. Cadila Recent Developments

Table 56. Apotex Basic Information List

Table 57. Apotex Description and Business Overview

Table 58. Apotex Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

Table 59. Revenue (US$ Million) in Drugs for Herpes Labialis (Oral Herpes) Business of Apotex (2019-2024)

Table 60. Apotex Recent Developments

Table 61. Daewoong Pharmaceutical Basic Information List

Table 62. Daewoong Pharmaceutical Description and Business Overview

Table 63. Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

Table 64. Revenue (US$ Million) in Drugs for Herpes Labialis (Oral Herpes) Business of Daewoong Pharmaceutical (2019-2024)

Table 65. Daewoong Pharmaceutical Recent Developments

Table 66. Livzon Basic Information List

Table 67. Livzon Description and Business Overview

Table 68. Livzon Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

Table 69. Revenue (US$ Million) in Drugs for Herpes Labialis (Oral Herpes) Business of Livzon (2019-2024)

Table 70. Livzon Recent Developments

Table 71. Luoxin Basic Information List

Table 72. Luoxin Description and Business Overview

Table 73. Luoxin Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

Table 74. Revenue (US$ Million) in Drugs for Herpes Labialis (Oral Herpes) Business of Luoxin (2019-2024)

Table 75. Luoxin Recent Developments

Table 76. Med shine Basic Information List

Table 77. Med shine Description and Business Overview

Table 78. Med shine Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

Table 79. Revenue (US$ Million) in Drugs for Herpes Labialis (Oral Herpes) Business of Med shine (2019-2024)

Table 80. Med shine Recent Developments

Table 81. Bayer (Campho Phenique) Basic Information List

Table 82. Bayer (Campho Phenique) Description and Business Overview

Table 83. Bayer (Campho Phenique) Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

Table 84. Revenue (US$ Million) in Drugs for Herpes Labialis (Oral Herpes) Business of Bayer (Campho Phenique) (2019-2024)

Table 85. Bayer (Campho Phenique) Recent Developments

Table 86. Blistex Basic Information List

Table 87. Blistex Description and Business Overview

Table 88. Blistex Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

Table 89. Revenue (US$ Million) in Drugs for Herpes Labialis (Oral Herpes) Business of Blistex (2019-2024)

Table 90. Blistex Recent Developments

Table 91. Kelun Basic Information List

Table 92. Kelun Description and Business Overview

Table 93. Kelun Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

Table 94. Revenue (US$ Million) in Drugs for Herpes Labialis (Oral Herpes) Business of Kelun (2019-2024)

Table 95. Kelun Recent Developments

Table 96. Hikma Basic Information List

Table 97. Hikma Description and Business Overview

Table 98. Hikma Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

Table 99. Revenue (US$ Million) in Drugs for Herpes Labialis (Oral Herpes) Business of Hikma (2019-2024)

Table 100. Hikma Recent Developments

Table 101. Haiwang Basic Information List

Table 102. Haiwang Description and Business Overview

Table 103. Haiwang Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

Table 104. Revenue (US$ Million) in Drugs for Herpes Labialis (Oral Herpes) Business of Haiwang (2019-2024)

Table 105. Haiwang Recent Developments

Table 106. Carmex Basic Information List

Table 107. Carmex Description and Business Overview

Table 108. Carmex Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

Table 109. Revenue (US$ Million) in Drugs for Herpes Labialis (Oral Herpes) Business of Carmex (2019-2024)

Table 110. Carmex Recent Developments

Table 111. Cipher Basic Information List

Table 112. Cipher Description and Business Overview

Table 113. Cipher Drugs for Herpes Labialis (Oral Herpes) Products, Services and Solutions

Table 114. Revenue (US$ Million) in Drugs for Herpes Labialis (Oral Herpes) Business of Cipher (2019-2024)

Table 115. Cipher Recent Developments

Table 116. Key Raw Materials Lists

Table 117. Raw Materials Key Suppliers Lists

Table 118. Drugs for Herpes Labialis (Oral Herpes) Downstream Customers

Table 119. Drugs for Herpes Labialis (Oral Herpes) Distributors List

Table 120. Research Programs/Design for This Report

Table 121. Key Data Information from Secondary Sources

Table 122. Key Data Information from Primary Sources

Table 123. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Drugs for Herpes Labialis (Oral Herpes) Product Picture

Figure 2. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value (2019-2030) & (US$ Million)

Figure 4. Drugs for Herpes Labialis (Oral Herpes) Report Years Considered

Figure 5. Global Drugs for Herpes Labialis (Oral Herpes) Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Drugs for Herpes Labialis (Oral Herpes) Revenue in 2023

Figure 7. Drugs for Herpes Labialis (Oral Herpes) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Aciclovir Picture

Figure 9. Valacyclovir Picture

Figure 10. Famciclovir Picture

Figure 11. Docosanol Picture

Figure 12. Other Picture

Figure 13. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 14. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value Market Share by Type, 2023 & 2030

Figure 15. Product Picture of External Use

Figure 16. Product Picture of Oral

Figure 17. Product Picture of Injection

Figure 18. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 19. Global Drugs for Herpes Labialis (Oral Herpes) Sales Value Market Share by Application, 2023 & 2030

Figure 20. North America Drugs for Herpes Labialis (Oral Herpes) Sales Value (2019-2030) & (US$ Million)

Figure 21. North America Drugs for Herpes Labialis (Oral Herpes) Sales Value by Country (%), 2023 VS 2030

Figure 22. Europe Drugs for Herpes Labialis (Oral Herpes) Sales Value (2019-2030) & (US$ Million)

Figure 23. Europe Drugs for Herpes Labialis (Oral Herpes) Sales Value by Country (%), 2023 VS 2030

Figure 24. Asia Pacific Drugs for Herpes Labialis (Oral Herpes) Sales Value (2019-2030) & (US$ Million)

Figure 25. Asia Pacific Drugs for Herpes Labialis (Oral Herpes) Sales Value by Country (%), 2023 VS 2030

Figure 26. South America Drugs for Herpes Labialis (Oral Herpes) Sales Value (2019-2030) & (US$ Million)

Figure 27. South America Drugs for Herpes Labialis (Oral Herpes) Sales Value by Country (%), 2023 VS 2030

Figure 28. Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Sales Value (2019-2030) & (US$ Million)

Figure 29. Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Sales Value by Country (%), 2023 VS 2030

Figure 30. Key Countries/Regions Drugs for Herpes Labialis (Oral Herpes) Sales Value (%), (2019-2030)

Figure 31. United States Drugs for Herpes Labialis (Oral Herpes) Sales Value, (2019-2030) & (US$ Million)

Figure 32. United States Drugs for Herpes Labialis (Oral Herpes) Sales Value by Type (%), 2023 VS 2030

Figure 33. United States Drugs for Herpes Labialis (Oral Herpes) Sales Value by Application (%), 2023 VS 2030

Figure 34. Europe Drugs for Herpes Labialis (Oral Herpes) Sales Value, (2019-2030) & (US$ Million)

Figure 35. Europe Drugs for Herpes Labialis (Oral Herpes) Sales Value by Type (%), 2023 VS 2030

Figure 36. Europe Drugs for Herpes Labialis (Oral Herpes) Sales Value by Application (%), 2023 VS 2030

Figure 37. China Drugs for Herpes Labialis (Oral Herpes) Sales Value, (2019-2030) & (US$ Million)

Figure 38. China Drugs for Herpes Labialis (Oral Herpes) Sales Value by Type (%), 2023 VS 2030

Figure 39. China Drugs for Herpes Labialis (Oral Herpes) Sales Value by Application (%), 2023 VS 2030

Figure 40. Japan Drugs for Herpes Labialis (Oral Herpes) Sales Value, (2019-2030) & (US$ Million)

Figure 41. Japan Drugs for Herpes Labialis (Oral Herpes) Sales Value by Type (%), 2023 VS 2030

Figure 42. Japan Drugs for Herpes Labialis (Oral Herpes) Sales Value by Application (%), 2023 VS 2030

Figure 43. South Korea Drugs for Herpes Labialis (Oral Herpes) Sales Value, (2019-2030) & (US$ Million)

Figure 44. South Korea Drugs for Herpes Labialis (Oral Herpes) Sales Value by Type (%), 2023 VS 2030

Figure 45. South Korea Drugs for Herpes Labialis (Oral Herpes) Sales Value by Application (%), 2023 VS 2030

Figure 46. Southeast Asia Drugs for Herpes Labialis (Oral Herpes) Sales Value, (2019-2030) & (US$ Million)

Figure 47. Southeast Asia Drugs for Herpes Labialis (Oral Herpes) Sales Value by Type (%), 2023 VS 2030

Figure 48. Southeast Asia Drugs for Herpes Labialis (Oral Herpes) Sales Value by Application (%), 2023 VS 2030

Figure 49. India Drugs for Herpes Labialis (Oral Herpes) Sales Value, (2019-2030) & (US$ Million)

Figure 50. India Drugs for Herpes Labialis (Oral Herpes) Sales Value by Type (%), 2023 VS 2030

Figure 51. India Drugs for Herpes Labialis (Oral Herpes) Sales Value by Application (%), 2023 VS 2030

Figure 52. Drugs for Herpes Labialis (Oral Herpes) Industrial Chain

Figure 53. Drugs for Herpes Labialis (Oral Herpes) Manufacturing Cost Structure

Figure 54. Channels of Distribution (Direct Sales, and Distribution)

Figure 55. Bottom-up and Top-down Approaches for This Report

Figure 56. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions